clinical trials for retatrutide peptide Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped First phase 3 data for

S.AnzaiA.et al (2019)

GLP-1 (7-36) has a short half life of less than 2 minutes, and like GIP, is rapidly degraded by the enzyme dipeptidyl peptidase IV (DPP-4), which is widely expressed in a number of sites, including the endothelial cells of small gut arterioles

(56) reported that the UCP-2 mRNA expression in intra-abdominal adipose tissue was significantly lower in obese subjects than that in lean ones

While on GLP-1 RAs, monitoring for vitamin B12 deficiency is recommended

However, there were distinct sex differences in patterns of fat distribution, blood glucose regulation, neurogenesis, inflammation and on PSD95 expression, though these effects were dependent on diet